At 9.1% CAGR, the Europe dPCR and qPCR Market is Projected to be Worth US$ 5,182.96 Million by 2030, Says Business Market Insights

According to Business Market Insights research, the Europe dPCR and qPCR market was valued at US$ 2,573.83 million in 2022 and is expected to reach US$ 5,182.96 million by 2030, registering a CAGR of 9.1% from 2022 to 2030. Growing adoption of PCR methods in emerging countries and increasing incidence of genetic and infectious diseases are among the critical factors attributed to the Europe dPCR and qPCR market expansion.

In recent years, molecular methods such as PCR have evolved as diagnostic technology. The method enables healthcare professionals to diagnose a wide range of infectious diseases accurately and is considered an indispensable research and diagnostic tool. PCR allows the generation of millions of DNA copies from one single strand of DNA. It also allows early diagnosis of disease and hence plays an essential role in disease control. PCR gives reproducible results that are comparable between different laboratories and hence are accepted worldwide. As PCR techniques are being widely accepted and utilized in emerging countries. Due to its simple, rapid, and highly specific screening of diseases and its increasing application in clinical microbiology, virology, parasitology, biotechnology, and allied fields, the Europe dPCR and qPCR market in developing countries is expected to experience lucrative opportunities during the forecast period.

On the contrary, high costs of PCR systems hampers the growth of Europe dPCR and qPCR market.

Based on treatment, the Europe dPCR and qPCR market is bifurcated into quantitative PCR (qPCR) and digital PCR (dPCR). The digital PCR (dPCR) segment held 73.5% share of the Europe dPCR and qPCR market in 2022, amassing US$ 1,891.85 million. It is projected to garner US$ 3,993.75 million by 2030 to expand at 9.8% CAGR during 2022-2030.

By product, the Europe dPCR and qPCR market is segmented into reagents & consumables, instruments, and software & services. The reagents & consumables segment held 60.6% share of the Europe dPCR and qPCR market in 2022, amassing US$ 1,559.90 million. It is projected to garner US$ 3,220.88 million by 2030 to expand at 9.5% CAGR during 2022-2030.

By application, the Europe dPCR and qPCR market is segmented into research application, clinical application, and forensic application. The clinical application segment held 58.1% share of the Europe dPCR and qPCR market in 2022, amassing US$ 1,495.68 million. It is projected to garner US$ 3,353.06 million by 2030 to expand at 10.6% CAGR during 2022-2030. The clinical application segment is further subsegmented into oncology testing, blood screening, infectious disease testing, and other applications.

By end user, the Europe dPCR and qPCR market is segmented into hospitals and diagnostic centers, pharmaceutical and biotechnology companies, research laboratories and academic institutes, forensic laboratories, and clinical research organizations. The hospitals and diagnostic centers segment held 58.1% share of the Europe dPCR and qPCR market in 2022, amassing US$ 1,495.68 million. It is projected to garner US$ 3,353.06 million by 2030 to expand at 10.6% CAGR during 2022-2030.

Based on country, the Europe dPCR and qPCR market is segmented into segmented into the UK, Germany, France, Spain, Italy, and the Rest of Europe. Germany held 25.3% share of Europe dPCR and qPCR market in 2022, amassing US$ 651.84 million. It is projected to garner US$ 1,406.26 million by 2030 to expand at 10.1% CAGR during 2022-2030.

Key players operating in the Europe dPCR and qPCR market are Abbott Laboratories, Thermo Fisher Scientific Inc, Takara Bio Inc, Qiagen NV, Standard BioTools Inc, Lepu Medical Technology Beijing Co Ltd, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc, and Agilent Technologies Inc, among others.




Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com